Related Experiment Video
Updated: Jun 26, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Newer therapeutic molecules for multiple myeloma
1Department of Medical Oncology, Tata Memorial Hospital, Dr. E. Borges Road, Parel, Mumbai - 400 012, India. drpreetesh@yahoo.co.in
Indian Journal of Cancer
|December 30, 2008
Summary
Newer therapies for multiple myeloma (MM) are emerging, targeting MM cell-bone marrow interactions. These novel treatments, including immunomodulatory drugs and proteasome inhibitors, offer hope beyond traditional chemotherapy.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma (MM) treatment has relied on glucocorticoids and cytotoxic chemotherapy.
- Despite advances, MM remains an incurable malignancy.
- Understanding MM cell-host bone marrow interactions is crucial for novel therapy development.
Purpose of the Study:
- To review recent advancements in novel anti-MM therapies.
- To focus on therapies progressing from preclinical to clinical stages.
- To highlight the role of MM biology in guiding new treatment strategies.
Main Methods:
- Literature review of novel anti-MM therapies.
- Medline search using terms 'Myeloma and Newer Drugs'.
- Screening of treatment guidelines from 1999 and 2008.
Main Results:
- Novel therapies capitalize on understanding MM cell-bone marrow interactions.
- Thalidomide and its immunomodulatory derivatives (IMiDs) show promise.
- Bortezomib, a proteasome inhibitor, represents a significant therapeutic advance.
Conclusions:
- Novel therapeutic strategies are being developed for multiple myeloma.
- Targeting MM biology and microenvironment interactions is key.
- Emerging therapies like IMiDs and bortezomib offer new hope for MM patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...